As evident from the growing importance of DNA Vaccines, the author endeavours to provide readers with a complete picture of the third generation vaccine technology in its new release Global DNA Vaccine Market Outlook 2020. The study depicts a comprehensive analysis of the various DNA Vaccines launched till date. Furthermore, the report also segments the market according to their end-users into human and animal segments.
The therapeutic breakup and geographical segmentation are also provided in the report. Till date, the majority of vaccines commercialized in the market are targeted for animals. However, increasing researches for developing DNA vaccines for humans and continuous development in the gene delivery methods have led to a rising interest of major pharmaceutical companies in the human DNA vaccines market.
Meanwhile, the report covers an estimated market size of the industry in 2014 and its future forecast till the year 2020. The market size has been projected for human, animal and therapeutic segments based on the pipeline analysis of key players in this sector. Separate section is devoted to the competitive landscape including major players, their commercialized products, and strength & weakness analysis.
Research has revealed that though the number of vaccines targeting the human clinical segment is comparatively less in number, their blockbuster sales made this market worth US$ 7 Billion during 2014. This is owing to growing awareness, increasing R&D investment, and better clinical outcomes over traditional vaccines.
Key Topics Covered:
1. Analyst View
2. Research Methodology
3. Third Generation/DNA Vaccine - An Introduction
4. Drivers & Challenges
5. DNA Vaccine Market Overview
6. Market Segmentation
7. Pipeline Analysis
8. Trends & Developments
9. Competitive Assessment
- GlaxoSmithKline - Merck & Co., Inc - Novartis - Pfizer Inc - Sanofi - VGX Animal Health (A Subsidiary of Inovio Biomedical) - Zoetis